Drug Screening in Whole Blood Using the Agilent 6546 LC/Q-TOF and the LC Screener Tool with Automated Sample Preparation

Importance of the topic

The emergence of new drugs and designer analogues poses a constant challenge to forensic and toxicology laboratories. Broadening analytical panels and enabling retrospective data mining are critical to keeping pace with illicit substances. High-resolution LC/Q-TOF mass spectrometry combined with automated sample preparation and dedicated screening software provides a powerful solution for rapid, sensitive, and comprehensive drug screening in whole blood.

Objectives and study overview

This work presents a streamlined workflow for routine screening of over 150 drugs and related metabolites in whole blood. Key aims include minimizing method development time, achieving fast chromatographic separation, ensuring robust data quality over extended use, and demonstrating the utility of the LC Screener Tool in MassHunter Quantitative Analysis 10.1 for fast review and reporting.

Methodology and instrumentation

Automated sample preparation was performed on an Agilent Bravo liquid handling platform using Captiva EMR—Lipid 96-well plates for protein precipitation and lipid removal. Extracts were dried under nitrogen, reconstituted, and transferred to deep-well plates sealed for LC injection. Chromatography employed an Agilent 1290 Infinity II LC with a Poroshell 120 EC-C18 column (2.1 × 100 mm, 2.7 μm) at 55 °C and a 10-minute gradient. Detection was carried out on the Agilent 6546 LC/Q-TOF with Jet Stream electrospray, using data-independent All Ions acquisition (0, 20, 40 eV CE) at 8 spectra/sec and dual reference masses for mass accuracy. Data analysis utilized MassHunter Quantitative Analysis 10.1 with the LC Screener Tool and a forensic toxicology personal compound database and library (PCDL).

Main results and discussion

• Chromatographic separation of 153 analytes was achieved in under 10 minutes, including baseline resolution of critical isobaric pairs.
• High-resolution data (R>30,000 at m/z 118) was maintained at fast acquisition, with accurate precursor and fragment spectra for reliable identification.
• Matrix effects were below 10% for 81% of analytes and under 20% for 97%, indicating excellent cleanup. Overall recovery was between 80–120% for 78% of compounds.
• Limits of detection in blood were ≤1 ng/mL for 63% of analytes, with RSD at the LOD below 5% for 46% of compounds, and below 20% in all cases.
• Carryover was negligible (<0.1% for most analytes). Longevity testing over 1,465 injections showed stable peak areas, retention times, and mass accuracy with minimal maintenance.
• Analysis of ten unknown forensic samples yielded rapid identification of multiple drugs and metabolites, and target analytes were quantified with calibration curves (1–250 ng/mL, R2>0.99).

Benefits and practical applications

This workflow enables high-throughput, fully automated sample preparation, reducing manual handling and increasing reproducibility. Data-independent acquisition on the LC/Q-TOF allows retrospective screening for new analytes without reacquisition. The LC Screener Tool organizes complex high-resolution data into user-friendly screens, accelerating review and reporting for hundreds of analytes in minutes. Simultaneous screening and quantitation streamline forensic toxicology operations.

Future trends and potential applications

Ongoing expansion of spectral libraries will extend coverage to emerging designer drugs. Integration of ion mobility separation and advanced AI-driven spectral interpretation may further improve selectivity and speed. Miniaturized or multiplexed sample preparation platforms could enhance throughput, while portable high-resolution mass spectrometers may enable on-site forensic screening.

Conclusion

The described automated workflow combining Agilent Bravo sample preparation, fast LC/Q-TOF acquisition, and LC Screener software delivers rapid, sensitive, and comprehensive drug screening in whole blood. Its robustness, minimal maintenance requirements, and ability to perform retrospective analysis make it well suited for routine forensic toxicology laboratories seeking to keep pace with evolving drug markets.